市場調查報告書
商品編碼
1085285

羥氯喹的全球市場:各適應症,各流通管道,各地區-規模,佔有率,展望,機會分析(2022年∼2028年)

Hydroxychloroquine Market, By Disease Indication, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

為了評估羥氯喹對冠狀病毒感染疾病患者的治療的有效性,主要企業增加聯盟和共同研究等無機成長策略,預期促進在預測期間內的羥氯喹市場成長。

本報告提供全球羥氯喹市場的相關調查,市場展望,市場動態,市場分析,競爭情形等全面性資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各適應症
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 法規情境
  • 產業趨勢
  • 合併和收購
  • 新的疾病適應症的認證/銷售
  • 推銷及行銷舉措
  • PEST分析

第1章 全球羥氯喹市場:各適應症(100萬美元)(2017年∼2028年)

  • 簡介
  • 瘧疾
  • 冠狀病毒病
  • 紅斑
  • 類風濕性關節炎

第2章 全球羥氯喹市場:各流通管道(100萬美元)(2017年∼2028年)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第3章 全球羥氯喹市場:各地區(100萬美元)(2017年∼2028年)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第4章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Sanofi SA
    • 適應症組合
    • Amneal Pharmaceuticals, Inc.
    • 適應症組合
    • Laurus Labs Limited
    • 適應症組合
    • Zydus Pharmaceuticals, Inc.
    • 適應症組合
    • Prasco Laboratories
    • 適應症組合
    • Dr. Reddy's Laboratories
    • 適應症組合
    • Cadila Pharmaceuticals
    • 適應症組合
    • Novartis International AG
    • 適應症組合
    • Concordia Pharmaceuticals Inc.
    • 適應症組合
    • Covis Pharmaceuticals, Inc.
    • 適應症組合
    • Cardinal Health
    • 適應症組合
    • Aphena Pharma Solutions Tennessee, Inc.
    • 適應症組合
    • Mylan NV
    • 適應症組合
    • McKesson Corporation
    • 適應症組合
    • Teva Pharmaceutical Industries Ltd
    • 適應症組合
    • Lupin Pharmaceutical
    • 適應症組合
    • Sun Pharmaceutical Industries Ltd
    • 適應症組合
  • 分析師的見解

第5章 Section

目錄
Product Code: CMI3727

Hydroxychlorquine has exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.

Despite the absence of strong evidence, the demand for hydroxychloroquine has spiked due to the coronavirus (COVID 19) outbreak. However, the doses of hydroxychloroquine need to be monitored, as its overdose can have dangerous side effects such as drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm, ventricular tachycardia, and ventricular fibrillation. This may lead to sudden respiratory and cardiac arrest, which can be fatal.

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period. For instance, on March 27, 2022, Rising Pharma Holdings Inc., a pharmaceutical company, entered into a collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease, to explore hydroxchloroquine as preventive treatment for coronavirus disease (COVID 19).

Key features of the study:

  • This report provides in-depth analysis of the global hydroxchloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hydroxchloroquine market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, disease indication up-gradation, market expansion, and marketing tactics
  • The global hydroxchloroquine market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hydroxchloroquine market

Detailed Segmentation:

  • Global Hydroxchloroquine Market, By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
  • Global Hydroxchloroquine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hydroxchloroquine Market, By Region:
    • North America
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Sanofi S.A.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Amneal Pharmaceuticals, Inc.
    • Laurus Labs Limited
    • Zydus Pharmaceuticals, Inc.
    • Prasco Laboratories
    • Dr. Reddy's Laboratories
    • Cadila Pharmaceuticals
    • Novartis International AG
    • Concordia Pharmaceuticals Inc.
    • Covis Pharmaceuticals, Inc.
    • Cardinal Health
    • Aphena Pharma Solutions Tennessee, Inc.
    • Mylan N.V.
    • McKesson Corporation
    • Teva Pharmaceutical Industries Ltd
    • Lupin Pharmaceutical
    • Sun Pharmaceutical Industries Ltd

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Industry Trend
  • Merger and Acquisitions
  • New Disease Indication Approvals/Launch
  • Promotion and Marketing Initiatives
  • PEST Analysis

1. Global Hydroxychloroquine Market, By Disease Indication, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Malaria
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Coronavirus Disease (COVID 19)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Lupus Erythematosus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Rheumatoid Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

2. Global Hydroxychloroquine Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

3. Global Hydroxychloroquine Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

4. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Sanofi S.A.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Amneal Pharmaceuticals, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Laurus Labs Limited
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Zydus Pharmaceuticals, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Prasco Laboratories
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Reddy's Laboratories
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cadila Pharmaceuticals
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis International AG
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Concordia Pharmaceuticals Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Covis Pharmaceuticals, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cardinal Health
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Aphena Pharma Solutions Tennessee, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan N.V.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • McKesson Corporation
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Lupin Pharmaceutical
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sun Pharmaceutical Industries Ltd
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

5. Section

  • References
  • Research Methodology
  • About us and Sales Contact